MLL-ENL-mediated leukemia initiation at the interface of lymphoid commitment

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Translocations involving the mixed lineage leukemia-1 (MLL) gene are common in acute leukemias.
• MLL fusions are associated with acute lymphoid leukemia (ALL) in humans but typically induce acute myeloid leukemia (AML) in murine models.

Purpose of the Study:

• To investigate the cellular and molecular mechanisms underlying the lineage restriction of MLL fusion-driven leukemias in a mouse model.
• To explore how genetic co-mutations and cell differentiation states influence leukemia development.

Main Methods:

• Utilized an inducible mixed lineage leukemia-eleven nineteen leukemia (MLL-ENL) mouse model.
• Examined the leukemia-initiating potential of various progenitor cell types.
• Assessed the impact of co-expressing MLL-ENL with a constitutively active RAS allele.
• Investigated the role of CEBPB-mediated transdifferentiation in B-cell progenitors.

Main Results:

• Early lymphoid progenitors, not just myeloid progenitors, can initiate AML in the MLL-ENL model.
• This myeloid potential in lymphoid progenitors is lost upon further lymphoid commitment.
• Co-expression with RAS affects disease latency and lineage assignment in a mutation-order-dependent manner.
• CEBPB-mediated transdifferentiation confers AML competence to otherwise incompetent B-cell progenitors.

Conclusions:

• MLL fusion leukemogenesis is influenced by the differentiation state of target cells and the order of genetic events.
• Transdifferentiation plays a role in converting committed progenitors to AML-competent cells.
• Findings suggest caution regarding therapeutic strategies based on transdifferentiation for MLL fusion-driven leukemias.